Merck Vioxx Sales Will Fall Short Of High Expectations, Firm Says
Executive Summary
Merck's Vioxx sales are showing the impact of a slower penetration rate of COX-2 inhibitors into the analgesic market, the company said June 22.
You may also be interested in...
COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says
The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.
COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says
The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.
Celebrex Growth Is "Typical" Of NSAIDs After Three Years, Pharmacia Says
Pharmacia's Celebrex is showing a growth curve that is typical for products in the non-steroidal anti-inflammatory class, CEO Fred Hassan acknowledged during a July 25 analysts call.